ILARIS DIN 02344939
Status: Cancelled Post Market
Holder: NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada record
| Active ingredient(s) | CANAKINUMAB 150 MG |
|---|
| Dosage form | Powder For Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L04AC08 CANAKINUMAB |
|---|
| Original market date | 27-Apr-2010 |
|---|
| Current status date | 13-Jan-2020 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Novartis Pharmaceuticals Canada Inc — licence 100273, currently licensed, last inspection rating C (2025-01-14).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CANAKINUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02460351 | ILARIS | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | CANAKINUMAB 150 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 11102 | 2010-02-26 | New Drug Submission (NDS) | |
Request a quote for ILARIS
How to read a Canadian DIN record